Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 42

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Molecular targets in heart failure gene therapy: current controversies and translational perspectives

Kairouz, Victor, Lipskaia, Larissa, Hajjar, Roger J., Chemaly, Elie R. · 2012 · Annals of the New York Academy of Sciences

Abstract

Use of gene therapy for heart failure is gaining momentum as a result of the recent successful completion of phase II of the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, which showed clinical safety and efficacy of an adeno‐associated viral vector expressing sarco‐endoplasmic reticulum calcium ATPase (SERCA2a). Resorting to gene therapy allows the manipulation of molecular targets not presently amenable to pharmacologic modulation. This short review focuses on the molecular targets of heart failure gene therapy that have demonstrated translational potential. At present, most of these targets are related to calcium handling in the cardiomyocyte. They include SERCA2a, phospholamban, S100A1, ryanodine receptor, and the inhibitor of the protein phosphatase 1. Other targets related to cAMP signaling are reviewed, such as adenylyl cyclase. MicroRNAs are emerging as novel therapeutic targets and convenient vectors for gene therapy, particularly in heart disease. We propose a discussion of recent advances and controversies in key molecular targets of heart failure gene therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2012.06520.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 59

  1. 10.1517/14712590903321462 · DOI · Paper page
  2. 10.1161/CIR.0b013e3182009701 · DOI · Paper page
  3. Gheorghiade M., 2011, Combining SERCA2a activation and Na‐K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output, Discov. Med., 12, 141
  4. 10.1093/eurheartj/ehr026 · DOI · Paper page
  5. 10.1161/CIRCULATIONAHA.111.022889 · DOI · Paper page
  6. 10.1161/CIRCULATIONAHA.109.890954 · DOI
  7. 10.1016/j.jacc.2010.11.023 · DOI
  8. 10.1161/CIRCULATIONAHA.105.592550 · DOI
  9. 10.1161/CIRCRESAHA.111.255687 · doi:10.1161/circresaha.111.255687
  10. 10.1161/CIRCULATIONAHA.108.770883 · DOI
  11. 10.1016/j.yjmcc.2010.11.011 · DOI
  12. 10.1161/CIRCEP.110.961615 · DOI · Paper page
  13. 10.1016/S0092-8674(00)81662-1 · DOI · Paper page
  14. 10.1161/hc0802.105564 · DOI · Paper page
  15. 10.1161/CIRCULATIONAHA.108.783852 · DOI · Paper page
  16. 10.1161/01.RES.0000163981.97262.3b · DOI
  17. 10.1016/j.jacc.2007.03.047 · DOI · Paper page
  18. 10.1016/j.bbrc.2011.04.023 · DOI
  19. 10.1016/S0008-6363(01)00487-4 · DOI · Paper page
  20. 10.1172/JCI17892 · DOI · Paper page
  21. 10.1089/hum.2011.035 · DOI
  22. 10.1074/jbc.M704056200 · DOI · Paper page
  23. 10.1172/JCI118446 · DOI · Paper page
  24. 10.1016/j.yjmcc.2011.04.006 · DOI
  25. 10.1093/cvr/cvr058 · DOI
  26. 10.1161/01.RES.0000161256.85833.fa · DOI · Paper page
  27. 10.1038/nature10407 · DOI · Paper page
  28. 10.1016/j.jacc.2011.04.032 · DOI
  29. 10.1016/j.jacc.2011.03.054 · DOI
  30. 10.1038/ncpcardio0309 · DOI
  31. 10.2217/14796678.3.4.413 · DOI
  32. 10.1161/CIRCRESAHA.108.173195 · DOI
  33. 10.1161/01.CIR.99.12.1618 · DOI · Paper page
  34. 10.1093/eurheartj/15.suppl_D.7 · doi:10.1093/eurheartj/15.suppl_d.7
  35. 10.1161/01.RES.0000102042.83024.CA · DOI · Paper page
  36. Ostrom R.S., 2000, Stoichiometry and compartmentation in G protein‐coupled receptor signaling: implications for therapeutic interventions involving G(s), J. Pharmacol. Exp. Ther., 294, 407, 10.1016/S0022-3565(24)39086-X · DOI · Paper page
  37. 10.1152/ajprenal.2000.279.3.F400 · DOI · Paper page
  38. 10.1146/annurev.pharmtox.41.1.145 · DOI · Paper page
  39. 10.1016/S0014-5793(98)00747-9 · doi:10.1016/s0014-5793(98)00747-9
  40. 10.1038/sj.bjp.0705976 · DOI
  41. 10.1152/ajpheart.00050.2009 · DOI
  42. 10.1016/S0008-6363(98)00283-1 · DOI
  43. 10.1021/bi991619k · DOI
  44. 10.1253/circj.CJ-08-0957 · DOI
  45. 10.1073/pnas.1733772100 · DOI · Paper page
  46. 10.1016/j.jacc.2010.11.052 · DOI
  47. 10.1074/jbc.M805825200 · DOI
  48. 10.1016/j.cellsig.2009.11.010 · DOI
  49. Lipskaia L., 2011, Compartmentalization of cAMP increase at the level of sarcoplasmic reticulum results in dilated and hypertrophic cardiomyopathy in aged transgenic mice, Eur. Heart J., 32, 999
  50. 10.1096/fj.02-0292fje · DOI
  51. 10.1096/fj.02-0784com · DOI
  52. 10.1002/eji.201041136 · DOI · Paper page
  53. 10.1136/hrt.2007.116483 · DOI
  54. 10.1016/j.pharmthera.2010.09.011 · DOI · Paper page
  55. 10.1016/j.yjmcc.2006.08.008 · DOI
  56. 10.2353/ajpath.2010.090451 · DOI
  57. 10.1097/FJC.0b013e3181f713fe · DOI
  58. 10.1161/CIRCRESAHA.110.227496 · DOI · Paper page
  59. Karakikes I., 2010, Abstract 20916: therapeutic cardiac‐targeted delivery of Mir‐1 reverses hypertrophy and preserves cardiac function in a pressure overload animal model, Circulation, 122, A20916

Cited by

See all 42

Metadata

Authors
Kairouz, V., Lipskaia, L., Hajjar, R. J., & Chemaly, E. R.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2012-04
Volume
1254
Issue
1
Pages
42-50
ISSN
  • 0077-8923
  • 1749-6632
Cited by
42
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.